Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in New York

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medications. This legacy context established a baseline of trust and awareness, particularly regarding the importance of informed patient decision-making. Within this framework, discussions of pharmaceutical safety have historically focused on common side effects and general risk profiles, often without delving into specific, rare adverse events linked to long-term use. As the scope of health information has evolved, a natural pivot occurs when examining the real-world implications of sustained medication exposure. In the domain of mass production and widespread prescription, certain drugs—such as bisphosphonates like Fosamax—have been associated with uncommon but serious conditions, including osteonecrosis of the jaw. This shift in focus moves from general health literacy to a more targeted occupational and clinical concern: the potential for cumulative exposure to create distinct risk scenarios. The transition here is not about mechanistic detail but about recognizing that broad health education must eventually address specific, actionable legal and medical questions—such as the statute of limitations for filing claims in jurisdictions like New York. This pivot reframes the conversation from passive awareness to active, context-specific risk management.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone turnover. A recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves pain, swelling, infection, and non-healing extraction sockets, and diagnosis is based on clinical examination and imaging. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve suppression of bone remodeling due to bisphosphonate accumulation in the jawbone, which has high turnover rates. This suppression impairs the ability to repair microdamage and respond to local insults such as dental procedures or infection. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In clinical trials, the incidence of ONJ was rare (https://pubmed.ncbi.nlm.nih.gov/42046648/), but post-marketing reports have documented cases.

Clinical Presentation, Onset, and Management of ONJ

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under Warnings and Precautions, describing the condition, associated risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, some patients and attorneys may argue that these warnings were not sufficiently prominent or timely, particularly given that ONJ can occur after prolonged use and may be triggered by routine dental procedures. The timeline between exposure and documented harm is variable; ONJ may develop months to years after starting Fosamax, and the condition can be chronic and debilitating.

Legal Considerations for Fosamax-Related ONJ Claims in New York

For affected patients in New York, attorney-related considerations include the statute of limitations for filing a product liability claim. In New York, the statute of limitations for personal injury claims is generally three years from the date of injury, but for medical malpractice or product liability, the timeline may differ and could be subject to discovery rules, meaning the clock starts when the injury is or should have been reasonably discovered. Patients diagnosed with ONJ after using Fosamax should consult with a qualified attorney promptly to assess their legal options, as delays could bar recovery. Evidence of the link between Fosamax and ONJ, as documented in FDA labeling and medical literature, may support claims that the manufacturer failed to adequately warn about this risk. However, each case is fact-specific, and factors such as the duration of use, presence of known risk factors, and timing of diagnosis will be critical. In summary, Fosamax is associated with a rare but serious risk of osteonecrosis of the jaw, with onset varying from days to months after initiation. The drug's label includes warnings about this risk, but patients who develop ONJ may have legal recourse under New York law, subject to applicable statutes of limitations. Affected individuals should seek both medical and legal advice to address their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, for product liability claims, the timeline may be subject to the discovery rule, meaning the clock starts when the injury is or should have been reasonably discovered. Patients should consult an attorney promptly to avoid missing the deadline.

What evidence links Fosamax to osteonecrosis of the jaw?

Fosamax's FDA label includes a specific warning about osteonecrosis of the jaw under Warnings and Precautions, describing the condition, risk factors, and management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical trials reported rare incidence (https://pubmed.ncbi.nlm.nih.gov/42046648/), but post-marketing cases have been documented.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.